lets see where your heads are...please think of both sides of the equation..INO's side for their decision and the retail people on the other............................go.....
Seems like their not done..I didn't get any response to my email to Bernie..I thought PR was his job title.I guess I'd hide too..
I got nailed to the cross for making that exact statement..no follow thru after r/s= slaughter and still nothing. I guess that's what we get for trusting..
4 three days..no big vol.just an agenda unfolding. Just as some buying comes in, someone has been coming rite. behind WITH 100 ON THE BID OR BELOW. Funds or organized raiders..naked short sellers.some times I think it's not about the stock anymore. I get the feeling it's more about everything else.
“When several drug companies repeatedly see big stock price dips due to a negative articles published at critical moments — especially when those dips benefit the financial interests of short sellers — it should raise serious questions at the SEC. Given the suspicious timing of Mr. Feuerstein’s articles, which include misinformation and innuendo, there should be an inquiry into whether there was a deliberate effort to manipulate the market for profit,” CREW Executive Director Melanie Sloan said.
CREW’s request for an investigation highlights several examples where Mr. Feuerstein’s blog posts and Twitter communications appear intended to send the stock prices plummeting of three pharmaceutical companies — Northest Biotherapeutics, GTx, and Mannkind — at a time when short shares were at a peak.
On June 18, 2014, Northwest Biotherapeutics’ stock was trading at $8.97, a near record high for the stock. Prior reporting from Smith on Stocks noted the “intense shorting program” aimed at the company’s stock and that the rising stock prices set the stage for a “major short squeeze.” The following morning, before trading began, Mr. Feuerstein posted a series of tweets hinting the company had received bad news related to testing of its promising cancer drug. He then posted a blog item criticizing the company for releasing interim testing data, and quoting a doctor not involved with the study who suggested the company’s release of data was both highly unusual and inappropriate. As a result, by the close of trading on June 19, the stock lost 20 percent of its value and has continued to slide.
CREW’s letter to the SEC also notes similar suspicious timing related to Mr. Feuerstein’s reporting on drug companies GTx and Mannkind. As GTx’s stock reached near-record levels in July 2013, Mr. Feuerstein published an article predicting the failure of a critical drug trial, citing an unnamed short seller as a source. Mr. Feuerstein refused to correct the multiple errors in his article despite a point-by-point refutation by a GTx investor posted on SA Similarly, in March 2014, Mr. Feuerstein published an article predicting a 60-percent chance the Food and Drug Administration (FDA) would reject the company’s new drug, Afrezza. By the end of the day, Mannkind’s shares were trading at a 10-month low. Contrary to Mr. Feurstein’s prognostication, on April 1, an FDA advisory committee granted marketing approval for Afreeza by a vote of 13 to 1.
“Where there is smoke, there’s often fire. Maybe it’s just a coincidence that Mr. Feuerstein’s unduly negative articles appear at critical moments for these companies, but it certainly merits an investigation,” Ms. Sloan said
That's funny,It wasn't rope a while back... Now it's rope,it was low hanging fruit !!While they pounded their chests.. So he can keep his contrite, short answers for the morons that follow them blindly.All I know a lot of good people have lost a lot of money here and he says "you cant push rope?"
I'm in since .57,so it's not being a sore looser.We've supported this co. for quite a while ..So rope boy..That's all you got??
Lets hear your story,you seem to be opinionated in unmatched stupidity..Are you happy..?? If so,your scary..